Table 1. Demographic and therapy details of HIV+ subjects enrolled.
| Acute/early subject ID | Sex | Age (years) | At study entry (baseline) | Days of therapy used during study | Therapies used during study | Days of therapy used during study | |||
|---|---|---|---|---|---|---|---|---|---|
|
|
|||||||||
| HIV RNA (copies/mL) | CD3+CD4+ (cells/mL) | CD3+CD8+ (cells/mL) | Days on therapy | ||||||
| 1 | M | 38 | 179,000 | 277 | 1,138 | 6 | 173 | Combivir | 173 |
| Kaletra | 173 | ||||||||
| 2 | M | 46 | 47,900 | 692 | 1,116 | 0 | 195 | Sustiva | 195 |
| Epivir | 179 | ||||||||
| Viread | 179 | ||||||||
| Truvada | 16 | ||||||||
| 3 | M | 38 | 437 | 587 | 611 | 23 | 168 | Trizivir | 168 |
| Sustiva | 168 | ||||||||
| 4 | M | 32 | 71,300 | 237 | 1,069 | 0 | 0 | None | – |
| 5 | M | 43 | 200,000 | 360 | 2,918 | 0 | 0 | None | – |
| 6 | M | 36 | 160,000 | 313 | 1,394 | 0 | 0 | None | – |
| 7 | M | 51 | >1,000,000 | 582 | 1,278 | 0 | 73 | Atripla | 73 |
| 8 | M | 32 | 277,000 | 336 | 815 | 0 | 72 | Atripla | 72 |
| 9 | M | 22 | 297,000 | 512 | 2,358 | 0 | 54 | Atripla | 54 |